The financial press is currently swooning over western royalty financing giants setting up shop in Hong Kong. The narrative is predictably neat: mainland Chinese biotech deals are surging, venture capital has dried up, and non-dilutive royalty funding is riding in like a white knight to save cash-strapped drug developers.
It is a beautiful story. It is also fundamentally wrong. Meanwhile, you can find other stories here: Why Wall Street Is Not Buying The New Fed Chair Hawkish Rhetoric.
Western-style royalty monetization, which achieved massive success in markets defined by predictable patent protection and high-margin pricing, cannot simply be copy-pasted into the current Chinese healthcare ecosystem. The assumption that Hong Kong can serve as a frictionless conduit for this specific asset class ignores structural realities. I have watched firms torch tens of millions trying to force western financial structures into regulatory environments that are actively hostile to them.
The crowd thinks we are witnessing the dawn of a new financing boom for Asian biotech. In reality, we are watching a capital mismatch of epic proportions. To explore the complete picture, check out the recent report by Investopedia.
The Flawed Premise of "Non-Dilutive" Salvation
To understand why this expansion is hitting a wall, you have to look at how a standard royalty transaction works. A financier advances upfront capital to a biotech company. In exchange, they buy a percentage of future top-line revenues from a specific drug.
On paper, everybody wins. The founders keep their equity, and the funders get a steady, bond-like yield backed by pharmaceutical sales.
But this model relies entirely on three pillars:
- Long, ironclad patent exclusivity.
- Predictable, high-margin commercial pricing.
- Transparent, auditable hospital procurement systems.
Remove those pillars, and the math completely disintegrates. In the mainland market, those pillars do not exist in a form that western risk models recognize.
The National Reimbursement Drug List is a Royalty Killer
The single biggest blind spot in the current optimistic commentary is the National Reimbursement Drug List (NRDL) negotiation process.
In the United States, a biotech firm launches a drug, sets a high list price, and negotiates incremental discounts with commercial insurers. The top-line revenue remains robust enough to skim off a 5% or 10% royalty while leaving the operator with plenty of runway.
In China, getting onto the NRDL is mandatory if you want volume. But the price of admission is brutal.
The state insurance fund routinely demands price cuts of 60% to 80% in exchange for formulary access. When your gross margins are slashed by three-quarters overnight, your top-line revenue shrinks drastically. If a biotech company has already pledged a fixed percentage of that top-line revenue to a Hong Kong-based royalty fund, the operational math turns toxic.
Imagine a scenario where a startup develops an innovative oncology asset. They project $100 million in peak local sales based on global pricing models and promise a 5% royalty to an investor. Following NRDL negotiations, the drug's price is cut by 75%. Peak sales drop to $25 million. The royalty investor still demands their cut, but the biotech company now lacks the margin to cover its actual manufacturing and distribution costs.
By taking on royalty debt tied to top-line revenue rather than net profit, the company has essentially signed its own death warrant. The funding was not "non-dilutive" at all; it was an anchor.
The Volume-Based Procurement Trap
Even if a drug manages to navigate the NRDL, it faces the specter of Volume-Based Procurement (VBP). Once a therapeutic class sees sufficient competition, the government steps in to buy in bulk, driving prices down to near-commodity levels.
Royalty financing is built on the assumption of predictable, long-term cash flow decay curves. Investors map out a ten-year horizon where sales peak and then slowly tail off as patents expire. VBP turns that smooth curve into a cliff. A drug can lose 90% of its domestic value in a single bidding cycle if a generic competitor undercuts them.
Western royalty models are mathematically incapable of pricing this level of binary political risk. When these funds price their capital, they must demand exorbitant yields to compensate for the VBP threat. This means the cost of capital becomes higher than traditional venture debt or even heavily dilutive equity rounds.
The Illusion of Hong Kong as a Legal Safe Haven
The second pillar of the lazy consensus is that structuring these deals through Hong Kong solves the cross-border legal risk. The theory goes that because Hong Kong operates under a familiar common law system, intellectual property rights and royalty contracts can be enforced cleanly.
This is a structural misunderstanding of how intellectual property cash flows actually exit the mainland.
If a mainland biotech firm sells a drug inside China, that revenue is collected in Renminbi by a domestic operating entity. To pay the royalty fund in Hong Kong, those funds must be converted to foreign currency and moved across the border. This triggers complex State Administration of Foreign Exchange (SAFE) regulations, withholding taxes, and intercompany service agreement scrutiny.
If the mainland operator encounters financial distress and stops paying, a judgment from a Hong Kong court does not magically seize cash from a bank account in Shanghai. Enforcing cross-border security interests on domestic pharmaceutical revenues is a bureaucratic nightmare. The legal plumbing is clogged, and no amount of press releases about opening new offices in Central will change that.
A Better Way Forward: Out-Licensing Over Royalty Monetization
For mainland biotech founders looking at these new Hong Kong funds, the advice is simple: walk away from standard domestic royalty monetization.
Instead of pledging domestic revenues that are subject to the whims of the NRDL and VBP, prioritize cross-border out-licensing agreements (the "Go Global" strategy).
If you have a truly innovative asset, license the ex-China rights to a global pharma player who can commercialize it in markets with predictable pricing power. You receive upfront milestone payments to fund your domestic operations, and you keep your clean domestic equity structure intact.
Let the global pharmaceutical giants take the western pricing risk, while you manage the low-margin, high-volume realities of the domestic market. Do not let a smooth-talking financier convince you that your mainland revenue stream can support a western capital structure. It can't.
Stop looking at royalty financing as a shortcut to liquidity. In the current regulatory climate, it is a structural mismatch that rewards the fund upfront and leaves the biotech founder holding an empty, marginless shell.
